Browsing Tag
European Neurofibromatosis Conference
1 post
Pasithea Therapeutics shares surge as FDA clears PAS-004 trial for rare genetic skin tumors
Pasithea Therapeutics stock rallies after FDA clearance for PAS-004. Explore its $45.7M cash position, NF1 opportunity and clinical risks.